115 related articles for article (PubMed ID: 12881402)
1. Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib.
Govindan R; Behnken D; Read W; McLeod H
Ann Oncol; 2003 Aug; 14(8):1330-1. PubMed ID: 12881402
[No Abstract] [Full Text] [Related]
2. Gefitinib: phase II and III results in advanced non-small cell lung cancer.
Kelly K; Averbuch S
Semin Oncol; 2004 Feb; 31(1 Suppl 1):93-9. PubMed ID: 14981586
[TBL] [Abstract][Full Text] [Related]
3. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
Miller VA; Johnson DH; Krug LM; Pizzo B; Tyson L; Perez W; Krozely P; Sandler A; Carbone D; Heelan RT; Kris MG; Smith R; Ochs J
J Clin Oncol; 2003 Jun; 21(11):2094-100. PubMed ID: 12775734
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
Gadgeel SM; Ruckdeschel JC; Heath EI; Heilbrun LK; Venkatramanamoorthy R; Wozniak A
J Thorac Oncol; 2007 Apr; 2(4):299-305. PubMed ID: 17409801
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant systemic therapies in early-stage non-small-cell lung cancer.
Schiller JH
Clin Lung Cancer; 2003 Sep; 5 Suppl 1():S29-35. PubMed ID: 14641992
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
7. [Iressa (gefitinib)].
Kudoh S; Yoshimura A; Gemma A
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1079-84. PubMed ID: 12938261
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib, a novel, orally administered agent for the treatment of cancer.
Ranson M; Wardell S
J Clin Pharm Ther; 2004 Apr; 29(2):95-103. PubMed ID: 15068398
[TBL] [Abstract][Full Text] [Related]
9. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes.
Baselga J
J Clin Oncol; 2002 May; 20(9):2217-9. PubMed ID: 11980990
[No Abstract] [Full Text] [Related]
10. ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program.
Pallis AG; Mavroudis D; Androulakis N; Souglakos J; Kouroussis C; Bozionelou V; Vlachonikolis IG; Georgoulias V
Lung Cancer; 2003 Jun; 40(3):301-7. PubMed ID: 12781429
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
Miyauchi E; Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T;
Jpn J Clin Oncol; 2015 Jul; 45(7):670-6. PubMed ID: 25877748
[TBL] [Abstract][Full Text] [Related]
12. Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations.
Yao S; Zhi X; Wang R; Qian K; Hu M; Zhang Y
Thorac Cancer; 2016 Sep; 7(5):543-548. PubMed ID: 27766784
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
Yokoyama Y; Sonobe M; Yamada T; Sato M; Menju T; Aoyama A; Sato T; Chen F; Omasa M; Date H
Int J Clin Oncol; 2015 Dec; 20(6):1122-9. PubMed ID: 25953679
[TBL] [Abstract][Full Text] [Related]
15. Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer.
Santoro A; Cavina R; Latteri F; Zucali PA; Ginanni V; Campagnoli E; Ferrari B; Morenghi E; Pedicini V; Roncalli M; Alloisio M; Ravasi G; Soto Parra HJ
Ann Oncol; 2004 Jan; 15(1):33-7. PubMed ID: 14679116
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
Kris MG; Natale RB; Herbst RS; Lynch TJ; Prager D; Belani CP; Schiller JH; Kelly K; Spiridonidis H; Sandler A; Albain KS; Cella D; Wolf MK; Averbuch SD; Ochs JJ; Kay AC
JAMA; 2003 Oct; 290(16):2149-58. PubMed ID: 14570950
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib--a novel targeted approach to treating cancer.
Herbst RS; Fukuoka M; Baselga J
Nat Rev Cancer; 2004 Dec; 4(12):956-65. PubMed ID: 15573117
[TBL] [Abstract][Full Text] [Related]
18. Down-staging of EGFR mutation-positive advanced lung carcinoma with gefitinib followed by surgical intervention: follow-up of two cases.
Levchenko EV; Moiseyenko VM; Matsko DE; Iyevleva AG; Ivantsov AO; Yargnian SM; Anisimov VV; Semionov II; Imyanitov EN
Onkologie; 2009 Nov; 32(11):674-7. PubMed ID: 19887873
[TBL] [Abstract][Full Text] [Related]
19. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
[TBL] [Abstract][Full Text] [Related]
20. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer.
Mohamed MK; Ramalingam S; Lin Y; Gooding W; Belani CP
Ann Oncol; 2005 May; 16(5):780-5. PubMed ID: 15728108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
